CureVac N.V. (CVAC) Earnings History
Profitable7 years of earnings data (2018–2024) · Positive TTM net income
Loading earnings history...
CureVac N.V. (CVAC) Earnings Overview
As of June 21, 2026, CureVac N.V. (CVAC) reported trailing twelve-month net income of $194M, reflecting +161.0% year-over-year growth. The company earned $0.86 per diluted share over the past four quarters, with a net profit margin of 30.3%.
Looking at the long-term picture, CVAC's historical earnings data spans multiple years. The company achieved its highest annual net income of $162M in fiscal 2024, representing a new all-time high.
CureVac N.V. maintains industry-leading profitability with a gross margin of 80.2%, operating margin of 33.2%, and net margin of 30.3%. This margin structure demonstrates strong pricing power and operational efficiency. View revenue history →
Compared to peers including MRNA (-$3.19B net income, -145.2% margin), BNTX (-$1.13B net income, -39.6% margin), ARCT (-$79M net income, -97.9% margin), CVAC has outperformed on profitability metrics. Compare CVAC vs MRNA →
CVAC Earnings vs Peers
Earnings metrics vs comparable public companies
CVAC Historical Earnings Data (2018–2024)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $162M | +162.3% | $178M | $0.72 | 30.3% | 33.2% |
| 2023 | -$260M | -4.5% | -$274M | $-1.18 | -484.0% | -510.1% |
| 2022 | -$249M | +39.5% | -$249M | $-1.32 | -369.4% | -370.0% |
| 2021 | -$412M | -219.0% | -$412M | $-2.21 | -399.8% | -400.3% |
| 2020 | -$129M | -29.2% | -$124M | $-0.98 | -264.0% | -253.6% |
| 2019 | -$100M | -40.2% | -$99M | $-0.53 | -573.5% | -571.3% |
| 2018 | -$71M | - | -$73M | $-0.40 | -553.5% | -565.8% |
Download Data
Export CVAC earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CVAC — Frequently Asked Questions
Quick answers to the most common questions about buying CVAC stock.
What is CVAC earnings per share (EPS)?
CVAC trailing twelve-month (TTM) diluted EPS is $0.86, reflecting +161.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2024 is available in the table on this page.
What is CureVac N.V.'s net income?
CureVac N.V. (CVAC) trailing twelve-month net income is $194M as of 2024. Earnings grew +161.0% year-over-year.
Is CVAC profitable?
Yes, CVAC is profitable with a TTM net income of $194M and a net profit margin of +30.3%.
What is CVAC's earnings growth rate?
CVAC compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2024.
What are CVAC's profit margins?
CureVac N.V. net profit margin is +30.3%, operating margin is +33.2%, and gross margin is +80.2%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is +26.7%.
Is CVAC growing earnings?
Yes, CVAC earnings are accelerating — EPS growth of +161.0% exceeds the 5-year CAGR of N/A. TTM net income reached $194M. Earnings momentum is strengthening.
What was CVAC's best earnings year?
CureVac N.V.'s highest annual net income on record is $162M, achieved in fiscal year 2024. Earnings history on this page spans 2018 to 2024 and includes all annual and quarterly figures.
What were CVAC's earnings last quarter?
CVAC's most recent reported quarter was Q2 2025. Net income was $-60M with diluted EPS of $-0.26. For a full breakdown of all quarters, see the quarterly earnings table on this page.